20,675 Shares in Insulet Corporation $PODD Bought by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. purchased a new position in Insulet Corporation (NASDAQ:PODD) during the fourth quarter, Holdings Channel reports. The firm purchased 20,675 shares of the medical instruments supplier’s stock, valued at approximately $5,877,000.

A number of other hedge funds also recently modified their holdings of the stock. Brown Advisory Inc. increased its position in shares of Insulet by 10.6% in the fourth quarter. Brown Advisory Inc. now owns 29,080 shares of the medical instruments supplier’s stock worth $8,266,000 after purchasing an additional 2,777 shares during the period. Aigen Investment Management LP bought a new position in shares of Insulet in the fourth quarter worth $290,000. Arrowstreet Capital Limited Partnership increased its position in shares of Insulet by 229.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 218,559 shares of the medical instruments supplier’s stock worth $62,123,000 after purchasing an additional 152,185 shares during the period. Kestra Advisory Services LLC increased its position in shares of Insulet by 22.5% in the fourth quarter. Kestra Advisory Services LLC now owns 3,881 shares of the medical instruments supplier’s stock worth $1,103,000 after purchasing an additional 714 shares during the period. Finally, CreativeOne Wealth LLC increased its position in shares of Insulet by 20.8% in the fourth quarter. CreativeOne Wealth LLC now owns 4,321 shares of the medical instruments supplier’s stock worth $1,228,000 after purchasing an additional 745 shares during the period.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. TD Cowen decreased their price target on Insulet from $379.00 to $294.00 and set a “hold” rating on the stock in a research report on Monday, June 1st. Robert W. Baird decreased their price target on Insulet from $360.00 to $248.00 in a research report on Thursday, May 7th. Royal Bank Of Canada restated an “outperform” rating and issued a $280.00 price target on shares of Insulet in a research report on Wednesday, May 27th. Raymond James Financial set a $216.00 target price on Insulet in a research report on Monday, June 8th. Finally, Oppenheimer decreased their target price on Insulet from $300.00 to $210.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Twenty-one analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $240.78.

Insulet Stock Performance

Insulet stock opened at $149.70 on Friday. Insulet Corporation has a 12-month low of $140.63 and a 12-month high of $354.88. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The business’s 50-day moving average price is $169.92 and its two-hundred day moving average price is $232.67. The stock has a market cap of $10.37 billion, a PE ratio of 34.81, a P/E/G ratio of 1.18 and a beta of 1.13.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter in the previous year, the business posted $1.02 earnings per share. The business’s revenue for the quarter was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, analysts expect that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Insider Transactions at Insulet

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director directly owned 9,041 shares in the company, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.36% of the stock is currently owned by corporate insiders.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.